Cervomed Inc. quarterly report, Q2 FY2014

Business context and reporting period

This is RestorGenex Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2014. The filing identifies the registrant as RestorGenex Corporation, formerly Stratus Media Group; this differs from the request metadata naming Cervomed Inc. RestorGenex had repositioned itself as a specialty biopharmaceutical company focused on dermatology, ophthalmology and women’s health, and had acquired Canterbury and Hygeia in 2013 and Paloma and VasculoMedics in March 2014. ProElite operations were discontinued.

Financial results and liquidity

Gross margin is not meaningful because the company reported no revenue. At June 30, cash and cash equivalents were $27.14 million, working capital was $25.31 million, total assets were $54.53 million, and total liabilities were $9.23 million. Current liabilities were $4.13 million. Notes payable were $715,000, with a further $200,000 related-party note shown in current liabilities; accrued interest was $592,609. The company reported no credit facilities. Contractual obligations were listed at approximately $6.80 million, including notes, rent, accrued board fees, consulting, employee contracts and accrued interest.

Six-month financing cash inflow was $32.01 million, primarily from equity financing; investing cash flow was zero. Cash increased by $26.88 million from $254,964 at year-end 2013. The company reported approximately $35.6 million gross and $31.3 million net proceeds from its private placement, which ran through July 10, 2014; therefore, the full placement proceeds were not all received by the June 30 balance-sheet date.

Material changes versus the prior comparable period

• Revenue remained zero in both the 2014 and 2013 second quarters and first halves.
• Second-quarter operating expenses declined 44% from $8.10 million to $4.51 million; first-half expenses declined 42% from $10.19 million to $5.88 million. Management attributed the decreases mainly to the shift away from entertainment and sports operations. 2013 included a $1.94 million ProElite impairment charge.
• The company moved from second-quarter 2013 continuing-operations income of $2.48 million to a second-quarter 2014 loss of $4.46 million. First-half continuing-operations results moved from income of $126,778 to a loss of $5.84 million. The 2013 comparisons included large gains from remeasurement and extinguishment of derivative liabilities, which did not recur in 2014.
• Cash and working capital improved substantially from December 31, 2013, when cash was $254,964 and working capital was negative $5.88 million, largely reflecting the 2014 equity raise.
• First-half research and development expense was $403,413, versus none in 2013; depreciation and amortization rose to $1.09 million, reflecting acquired intangible assets and amortization of an advisory-services arrangement.

Outlook, commentary, risks and unusual items

• Management expected continuing losses and higher research and development and general and administrative costs as it advanced its products. It believed June 30 cash would fund planned operations for at least 12 months, but cautioned that additional funding might be needed sooner. Proceeds were intended for research and development and working capital.
• Management described CL-214 as potentially ready for launch in the fourth quarter of 2015 or early 2016, and said it was planning Phase I/Phase II studies of P529 for age-related macular degeneration. These are plans, not assured milestones or approvals.
• The company cited development, clinical and regulatory execution, commercialization, financing, dilution, key-personnel and intellectual-property risks. It had no credit facility and warned that lack of financing could require delays, changes to development plans or strategic alternatives.
• Goodwill and intangible assets totaled approximately $25.03 million. Management reported no company-wide impairment at June 30 but noted possible reporting-unit impairment and planned annual reporting-unit testing. A significant impairment could result in a charge up to the carrying value.
• A property-damage claim of $393,592 was accrued; the company disputed insurance coverage and intended to defend the claim. The ASC creditor settlement was paid and had no remaining liability at June 30.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses involving segregation of duties, written controls over contracts and commitments, and accounting-system change controls. Management also noted a late Form 8-K/A filing and described remediation steps, including hiring a CFO and controller.
• Unusual noncash charges included a $2.71 million charge related to shares and warrants issued in conversion of $1.05 million of chairman-held notes, and a $1.83 million loss on settling that related-party debt. The private placement included warrants and resulted in substantial share issuance and potential dilution.

Important facts for investors to verify

1. Confirm the registrant identity: the supplied filing is for RestorGenex Corporation, not Cervomed Inc.
2. Review the private-placement terms, net proceeds received by June 30 versus after quarter-end, placement fees, warrants and resulting dilution.
3. Assess the development status, funding needs and feasibility of the company’s stated product and clinical timelines; the filing reports no revenue.
4. Examine the basis for goodwill and intangible-asset valuations and the planned reporting-unit impairment testing.
5. Monitor remediation of disclosed material weaknesses and the status and insurance coverage of the accrued property-damage claim.